Cargando…

Can Pharmacogenetic Variants in TPMT, MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?

Systemic sclerosis (SSc) is a rare connective tissue disorder with highest morbidity and mortality among rheumatologic diseases. Disease progression is highly heterogeneous between patients, implying a strong need for individualization of therapy. Four pharmacogenetic variants, namely TPMT rs1800460...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jelovac, Marina, Kotur, Nikola, Ristivojevic, Bojan, Pavlovic, Djordje, Spasovski, Vesna, Damjanov, Nemanja, Pavlovic, Sonja, Zukic, Branka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217985/ https://www.ncbi.nlm.nih.gov/pubmed/37239884 http://dx.doi.org/10.3390/ijms24108538

Ejemplares similares

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations
por: Stanković, Biljana, et al.
Publicado: (2020)

Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia
por: Milosevic, Goran, et al.
Publicado: (2018)

Genome-Wide Association Study of COVID-19 Outcomes Reveals Novel Host Genetic Risk Loci in the Serbian Population
por: Zecevic, Marko, et al.
Publicado: (2022)

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment
por: Kotur, Nikola, et al.
Publicado: (2020)

Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis
por: Jančić, Ivan, et al.
Publicado: (2015)

Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment
por: Pavlovic, Sonja, et al.
Publicado: (2019)

Machine Learning Modeling from Omics Data as Prospective Tool for Improvement of Inflammatory Bowel Disease Diagnosis and Clinical Classifications
por: Stankovic, Biljana, et al.
Publicado: (2021)

Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection
por: Klaassen, Kristel, et al.
Publicado: (2020)

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2022)

UGT1A1 (TA)(n) Promoter Genotype: Diagnostic and Population Pharmacogenetic Marker in Serbia
por: Vukovic, M, et al.
Publicado: (2018)

Expression Profiles of Long Non-Coding RNA GAS5 and MicroRNA-222 in Younger AML Patients
por: Pavlovic, Djordje, et al.
Publicado: (2021)

Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused By Chronic Hepatitis C
por: Jordovic, Jelena, et al.
Publicado: (2019)

Association of Vitamin D, Zinc and Selenium Related Genetic Variants With COVID-19 Disease Severity
por: Kotur, Nikola, et al.
Publicado: (2021)

Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2018)

Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children
por: Li, Qian, et al.
Publicado: (2019)

Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
por: Taylor, Zachary L., et al.
Publicado: (2021)

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines
por: Bhavsar, Amit P., et al.
Publicado: (2017)

Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2019)

Molecular Biomarkers in Perthes Disease: A Review
por: Spasovski, Vesna, et al.
Publicado: (2023)

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition
por: Ni, Wenjun, et al.
Publicado: (2010)

Novel Patched 1 mutations in patients with nevoid basal cell carcinoma syndrome – case report
por: Škodrić-Trifunović, Vesna, et al.
Publicado: (2015)

SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study
por: Luo, Jian-Quan, et al.
Publicado: (2015)

Case Report: Successful Therapy of Spontaneously Occurring Canine Degenerative Lumbosacral Stenosis Using Autologous Adipose Tissue-Derived Mesenchymal Stem Cells
por: Mrkovački, Janko, et al.
Publicado: (2021)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
por: Stojiljkovic, Maja, et al.
Publicado: (2012)

Pharmacogenetic analysis of inter-ethnic variability in the uptake transporter SLCO1B1 gene in Colombian, Mozambican, and Portuguese populations
por: Nega, Mulata Haile, et al.
Publicado: (2023)

Crosstalk between Glycogen-Selective Autophagy, Autophagy and Apoptosis as a Road towards Modifier Gene Discovery and New Therapeutic Strategies for Glycogen Storage Diseases
por: Andjelkovic, Marina, et al.
Publicado: (2022)

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
por: Rodrigues, Alice C., et al.
Publicado: (2011)

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
por: Lönnberg, K. Ivar, et al.
Publicado: (2023)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

The first insight into the genetic structure of the population of modern Serbia
por: Drljaca, Tamara, et al.
Publicado: (2021)

In Vitro Protein Stability of Two Naturally Occurring Thiopurine S-Methyltransferase Variants: Biophysical Characterization of TPMT*6 and TPMT*8
por: Wennerstrand, Patricia, et al.
Publicado: (2017)

One amino acid makes a difference–Characterization of a new TPMT allele and the influence of SAM on TPMT stability
por: Iu, Yan Ping Heidi, et al.
Publicado: (2017)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022)

SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer
por: Huang, Liu, et al.
Publicado: (2013)

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers
por: León-Cachón, Rafael B. R., et al.
Publicado: (2016)

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
por: Stewart, Alison
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jcjgc54qu7d2ik1hd9q5a5cdun